Long-Term Outcomes of Scleroderma Renal Crisis PDF Print E-mail
Monday, 14 December 2009 20:34
taken from http://www.flickr.com/photos/duncan/104321008/ via creative commonsIn a previous study. researchers sought to describe the medical history of a group of patients with Scleroderma Renal Crisis who had been treated with ACE inhibitors. The following is essentially a summary of that study, which was conducted by Virginia D. Steen, MD, and Thomas A. Medsger Jr., MD.

Scleroderma is a disease of unknown cause that produces fibrosis (hardening or scarring) of the connective tissue in the skin, blood vessels, and internal organs. These changes result in a tight, shiny appearance of the skin and potentially life-threatening abnormalities of the lungs, heart, digestive tract, and kidneys.

When Scleroderma involves the kidneys, it begins very suddenly with the onset of severely high blood pressure; this is called Scleroderma Renal Crisis. Without treatment, kidney failure requiring dialysis can develop and patients may die quickly. Dialysis involves connecting a person whose kidneys do not work to an artificial machine that filters waste products out of the blood.

The introduction more than 20 years ago of blood pressure drugs called angiotensin-converting enzyme (ACE) inhibitors has greatly improved the ability to treat Scleroderma Renal Crisis in the short term.

A group of researchers followed patients for up to 10 years after they had been treated with ACE inhibitors for Scleroderma Renal Crisis. Patients continued receiving ACE inhibitors after initial treatment. They also tried to identify factors that were related to better outcomes and determined patients' long-term outcomes.

Of the 145 patients studied with Scleroderma Renal Crisis, 89 had good long-term outcomes: 55 never required dialysis, and 34 (55% of those who initially required dialysis) had only temporary dialysis. Temporary dialysis lasted for an average of 8 months, and all patients were able to stop it by 18 months. Twenty-eight patients died within 6 months, and another 28 needed permanent dialysis.

This study included only patients treated at a single center, within a teaching hospital in Pittsburgh, Pennsylvania. Since patients treated with ACE inhibitors were not compared with others who did not receive this treatment, the study does not definitively prove that ACE inhibitors were the reason for the good outcomes. However, long-term outcomes were good in a substantial number of patients with Scleroderma Renal Crisis who were treated with ACE inhibitors.

For a link to Dr. Steen and Medsger's original and full article, do click here. For those of you who are logged in however, you can click on the link below to view the article directly.
 
More articles :

» Finding Reliable Health Information Online

As Internet users quickly discover, an enormous amount of health information is available online. Finding accurate and reliable information on genetic and rare diseases among the millions of online sources is a difficult task for almost everyone. We...

» Capillaroscopy, Autoantibody Findings Predict Raynaud's Progression

Abnormal findings on nailfold and the presence of scleroderma-specific autoantibodies in patients presenting with new-onset without overt connective tissue disease are powerful independent predictors of progression to definite .A landmark Canadian...

» Scleroderma Renal Crisis: A Pathology Perspective

Ibrahim Batal, Robyn T. Domsic, Thomas A.Medsger Jr., and Sheldon BastackyInternational Journal of RheumatologyVolume 2010, Article ID 543704Scleroderma renal crisis (SRC) is an infrequent but serious complication of systemic sclerosis (SSc). It is...

» PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials

Ann J. Impens, Kristine Phillips, and Elena SchiopuReceived 2 June 2011; Accepted 2 August 2011Phosphodiesterases (PDEs) are isoenzymes that control the level of intracellular cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate...

» Xerostomia one of the Sjögren’s Syndrome Symptoms

“The American Health Institute spent $8 million for a research diagnosis of Sjögren syndrome in several countries as an important disease with high impact on society,” he told The Capital Dr. Ricardo Bazet, ophthalmologist, director of Rosario...

» Donating Kidney Doesn't Shorten Lifespan

A study of over 80,000 American live kidney donors found they were likely to live just as long as people who have two healthy kidneys and that the procedure carries very little medical risk.You can read about the by lead author and transplant...